Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells

Cancer Gene Therapy

Volumn 12, Issue 3, 2005, Pages 304-312

  Liu, Yong ^a   Chiriva Internati, Maurizio ^b   You, Changxuan ^c   Luo, Rongcheng ^c   You, Hong ^a   Prasad, C Krishna ^a   Grizzi, Fabio ^d   Cobos, Everardo ^b   Klimberg, V Suzanne ^a   Kay, Helen ^a   Mehta, Jawahar L ^a   Hermonat, Paul L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b TEXAS TECH UNIVERSITY   (United States)

^c FIRST MILITARY MEDICAL UNIVERSITY   (China)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Adeno associated virus; BA46; Breast cancer; Cytotoxic T lymphocyte; Dendritic cell; Immunology

Indexed keywords

BA46 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; LACTADHERIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MILK PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER PATIENT; CELL POPULATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HEMATOPOIETIC CELL; IMMUNOTHERAPY; INTRADUCTAL CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS GENE;

ANTIBODIES; ANTIGENS, SURFACE; BLOTTING, SOUTHERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DENDRITIC CELLS; DEPENDOVIRUS; DNA PRIMERS; FLOW CYTOMETRY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-4; MILK PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS 2;

EID: 20044366384     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700785     Document Type: Article

References (41)

1. Correa I, Plunkett T. Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition. Breast Cancer Res. 2001;3:399-403.
2. Sotiriadou R, Perez SA, Gritzapis AD, et al. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer. 2001;85:1527-1534.
3. zum Buschenfelde CM, Metzger J, Hermann C, et al. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. J Immunol. 2001;167:1712-1719.
4. Kim DK, Lee TV, Castilleja A, et al. Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. Anticancer Res. 1999;19:2907-2916.
5. Peoples GE, Anderson BW, Lee TV, et al. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers. Clin Cancer Res. 1999;5:4214-4223.
6. Larocca D, Peterson JA, Urrea R, et al. A Mr 46,000 human milk fat globule protein that is highly expressed in human breast tumors contains factor VIII-like domains. Cancer Res. 1991;51:4994-4998.
7. Giuffrida MG, Cavaletto M, Giunta C, et al. Isolation and characterization of full and truncated forms of human breast carcinoma protein BA46 from human milk fat globule membranes. J Protein Chem. 1998;17:143-148.
8. Couto JR, Taylor MR, Godwin SG, et al. Cloning and sequence analysis of human breast epithelial antigen BA46 reveals an RGD cell adhesion sequence presented on an epidermal growth factor-like domain. DNA Cell Biol. 1996;15:281-286.
9. Taylor MR, Couto JR, Scallan CD, et al. Lactadherin (formerly BA46), a membrane-associated glycoprotein expressed in human milk and breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion. DNA Cell Biol. 1997;16:861-869.
10. Steinman RA. The dendritic cell system and its role in immunogenicity. Ann Rev Immunol. 1991;9:271-296.
11. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-1118.
12. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994;180:83-93.
13. Young JW, Inaba K. Dendritic cells as adjuvants for class 1 major histocompatibility complex-restricted antitumor immunity. J Exp Med. 1996;183:7-11.
14. Zivotgel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulationm and T helper cell I-associated cytokines. J Exp Med. 1996;183:87.
15. Paglia P, Chiodoni C, Rodolfo M, et al. Murine dendritic cells loaded in vitro with soluable protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med. 1996;183:317-322.
16. Alexander M, Salgaller M, Leseban C, et al. Generation of tumor-specific cytotoxic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 BA46 epitope. Am J Obstet Gynecol. 1996;175:1586-1593.
17. Philip R, Brunette E, Ashton J, et al. Transgene expression in dendritic cells to induce antigen-specific cytotoxic T cells in healthy donors. Cancer Gene Ther. 1998;5:236-246.
18. McArthur JG, Mulligan RC. Induction of protective antitumor immunity by gene-modified dendritic cells. J Immunother. 1998;21:41-47.
19. Sonderbye L, Feng S, Yacoubian S, et al. In vivo and in vitro modulation of immune stimulatory capacity of primary dendritic cells by adenovirus-mediated gene transduction. Exp Clin Immunogenet. 1998;15:100-111.
20. Kim CJ, Prevette T, Cormier J, et al. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J Immunother. 1997;20:276-286.
21. Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA. 1984;81:6466-6470.
22. Laface D, Hermonat PL, Wakeland EK, et al. Gene transfer into hematopoietic progenitor cells mediated by an adenoassociated virus vector. Virology. 1988;162:483-486.
23. Zhou SZ, Broxmeyer HE, Cooper S, et al. Adeno-associated virus 2-mediated gene transfer in murine hematopoietic progenitor cells. Exp Hematol. 1993;21:928-933, 1993.
24. Fisher-Adams G, Wong Jr KK, Podsakoff G, et al. Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction. Blood. 1996;88:492-504.
25. Liu Y, Santin AD, Mane M, et al. Transduction and utility of the granulocyte macrophage-colony stimulating factor gene into Monocytes and dendritic cells by adeno-associated virus. J Infect Cytokin Res. 2000;20:21-30.
26. Chiriva-Internati M, Liu Y, Salati E, et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papilloma-virus type 16 E7 antigen gene transduction into dendritic cells. Eur J Immunol. 2002;32:30-38.
27. Liu Y, Chiriva-Internati M, Grizzi F, et al. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Ther. 2001;8:948-957.
28. Helsloot J, Sturgess A. T cell reactivity to Sjogren's syndrome related antigen La(SSB). J Rheumatol. 1997;24:2340-2347.
29. Kusunoki Y, Huang H, Fukuda Y, et al. A positive correlation between the precursor frequency of cytotoxic lymphocytes to autologous Epstein-Barr virus-transformed B cells and antibody titer level against Epstein-Barr virus-associated nuclear antigen in healthy seropositive individuals. Microbiol Immunol. 1993;37:461-469.
30. Collaco RF, Cao X, Trempe JP. A helper virus-free packaging system for recombinant adeno-associated virus vectors. Gene. 1999;238:397-405.
31. You H, Liu Y, Carey MJ, et al. Defective 3A trophoblast-endometrial cell adhesion, and altered 3A growth and survival by human papillomavirus type 16 oncogenes. Mol Cancer Res. 2003;1:25-31.
32. Auricchio A, Hildinger M, O'Connor E, et al. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther. 2001;12:71-76.
33. Santin AD, Hermonat PL, Ravaggi A, et al. Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol. 2000;74:4729-4737.
34. Pala P, Verhoef A, Lamb JR, et al. Single cell analysis of cytokine expression kinetics by human CD4+ T-cell clones during activation or tolerance induction. Immunology. 2000;100:209-216.
35. Carmon L, Bobilev-Priel I, Brenner B, et al. Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)-beta2m transgenic mice. J Clin Invest. 2002;110:453-462.
36. Kruger W, Lohner R, Jung R, et al. Expression of human milk fat globulin proteins in cells of haemopoietic origin. Br J Cancer. 2000;83:874-879.
37. Russell DW, Miller AD, Alexander IE. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci USA. 1994;91:8915-8919.
38. Russell DW, Alexander IE, Miller AD. DNA synthesis and topoisomerase inhibitors increase transduction by adenoassociated virus vectors. Proc Natl Acad Sci USA. 1995;92:5719-5723.
39. Chiriva-Internati M, Liu Y, Grizzi F, et al. Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood. 2003;102:3100-3107.
40. Masten BJ, Yates JL, Pollard Koga AM, et al. Characterization of accessory molecules in murine lung dendritic cell function: roles for CD80, CD86, CD54, and CD40L. Am J Respir Cell Mol Biol. 1997;16:335-342.
41. Sun JY, Krouse RS, Forman SJ, et al. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. Cancer Res. 2002;62:3175-3183.